Abstract
Cempra conducted a randomized, double-blinded Phase 3 trial which evaluated the efficacy and safety of oral solithromycin (5 days) compared to the oral fluoroquinolone, moxifloxacin (7 days), for the treatment of adult patients with CABP. As pneumococcal vaccines are becoming widely used worldwide, including PCV13 (children) and PPSV23 (adults), this phase 3 trial presented a unique opportunity to further evaluate the overall prevalence of pneumococcal types causing CABP, the correlation between the pneumococcal type isolated from the nasopharynx and those strains isolated from blood or sputum and the use of pneumococcal density in nasopharyngeal specimens for detecting pneumococcal pneumonia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
